Press Releases

Press Releases

March 24, 2020
BOSTON , March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , announced today that its board of directors has appointed Damien McDevitt , Ph.D. as Chief Executive Officer, effective immediately.  Dr.
March 11, 2020
BOSTON , March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced that Lisa Johnson-Pratt , M.D., has joined the company as senior vice president of new product strategy. In this role, Dr.
February 28, 2020
Company builds awareness of hATTR amyloidosis and FCS via social media campaign, and will host special event with employees, patients and caregivers BOSTON , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
February 26, 2020
BOSTON , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt , Interim CEO, will
February 25, 2020
Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million Achieved the 2-2-2 plan: launched two products, initiated two phase 3 programs and reported positive phase 2 data on two pipeline programs Conference Call Webcast
February 18, 2020
Webcast scheduled for Tuesday, February 25 at 4:30 p.m. Eastern Time BOSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Tuesday, February 25 at 4:30 p.m.
February 13, 2020
BOSTON , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced the appointment of Amber Salzman , Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr.
January 28, 2020
Favorable safety and tolerability were observed P rimary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD, Calif. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
January 22, 2020
Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Primary and key secondary endpoints were met with significant reduction in apoC-III and triglyceride levels More than 90% of patients achieved serum triglycerides ≤ 150 mg/dL at the highest monthly
January 10, 2020
BOSTON and CARLSBAD, Calif. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular